Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance.

导出 LinkOut

翻译打印收藏纠错

第一作者： Xiao,Su

第一单位： International Joint Cancer Institute, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.

作者： Xiao,Su ^[1] ; Hao,Song ^[1] ; Fangfang,Niu ^[2] ; Kaixuan,Yang ^[3] ; Geng,Kou ^[1] ; Xiaohang,Wang ^[1] ; Huaiwen,Chen ^[1] ; Wei,Li ^[2] ; Shangjing,Guo ^[4] ; Jun,Li ^[1] ; Bohua,Li ^[1] ; Si-Shen,Feng ^[2] ; Jianxin,Jiang ^[2] ; Chuan,Yin ^[2] ; Jie,Gao ^[1]

作者单位： International Joint Cancer Institute, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, China. ^[1] College of Pharmacy, Liaocheng University, 1 Hu'nan Road, Liaocheng, Shandong 25200, PR China. ^[2] Centre for Stem Cell & Regenerative Medicine, Liaocheng People's Hospital, 67 Dongchang West Road, Liaocheng, Shangdong 252000, China. ^[3] Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China. ^[4] Department of Chemical & Biomolecular Engineering, National University of Singapore, Block E5, 02-11, 4 Engineering Drive 4, Singapore 117576, Singapore. ^[5] Suzhou NanoStar Biopharm Inc Ltd, BioBay, Bld B2, Unit 604, 218 Xing-Hu Street, Suzhou Industrial Park, Suzhou 215123, China. ^[6] Department of Hepatobiliary Surgery, Hubei Province Tumor Hospital, Wuhan, Hubei 430079, China. ^[7] Department of Pharmaceutical Sciences, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China. ^[8]

关键词 cancer nanotechnology glucosylceramide synthase molecular biomaterials multidrug resistance nanomedicine pharmaceutical nanotechnology